Maravai Lifesciences Holdings Inc Total Assets
Maravai Lifesciences Holdings Inc total assets. Based on the latest financial reports, Maravai Lifesciences Holdings Inc (MRVI) holds total assets worth $603.75 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Maravai Lifesciences Holdings Inc stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Maravai Lifesciences Holdings Inc (2018–2025)
Total assets of Maravai Lifesciences Holdings Inc from 2018 to 2025. This chart illustrates how Maravai Lifesciences Holdings Inc's total assets have evolved over time, based on quarterly financial data. See latest Maravai Lifesciences Holdings Inc stock price today for real-time trading data and today's change.
Maravai Lifesciences Holdings Inc - Asset Composition Analysis
Maravai Lifesciences Holdings Inc Total Assets Breakdown (December 2025)
Maravai Lifesciences Holdings Inc total assets breakdown as of December 2025. Maravai Lifesciences Holdings Inc's total assets of $603.75 Million consist of 38.5% current assets and 61.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.2% |
| Accounts Receivable | $25.50 Million | 3.3% |
| Inventory | $40.49 Million | 5.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $151.54 Million | 19.7% |
| Goodwill | $129.43 Million | 16.8% |
Asset Composition Trend (2018–2025)
This chart illustrates how Maravai Lifesciences Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore MRVI current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Maravai Lifesciences Holdings Inc's current assets represent 38.5% of total assets in 2025, an increase from 10.0% in 2018.
- Cash Position: Cash and equivalents constituted 28.2% of total assets in 2025, up from 4.1% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 35.0% of total assets, a decrease from 81.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 19.7% of total assets.
Maravai Lifesciences Holdings Inc Competitors by Total Assets
Key competitors of Maravai Lifesciences Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Maravai Lifesciences Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.05 | 5.16 | 6.01 |
| Quick Ratio | 2.98 | 4.49 | 5.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $117.24 Million | $290.08 Million | $573.13 Million |
Maravai Lifesciences Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Maravai Lifesciences Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.24 |
| Latest Market Cap to Assets Ratio | 1.49 |
| Asset Growth Rate (YoY) | -23.6% |
| Total Assets | $770.58 Million |
| Market Capitalization | $1.15 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Maravai Lifesciences Holdings Inc's assets above their book value (1.49x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Maravai Lifesciences Holdings Inc's assets decreased by 23.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Maravai Lifesciences Holdings Inc (2018–2025)
The table below shows the annual total assets of Maravai Lifesciences Holdings Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $770.58 Million | -23.57% |
| 2024-12-31 | $1.01 Billion | -32.22% |
| 2023-12-31 | $1.49 Billion | -34.83% |
| 2022-12-31 | $2.28 Billion | +18.98% |
| 2021-12-31 | $1.92 Billion | +50.96% |
| 2020-12-31 | $1.27 Billion | +119.92% |
| 2019-12-31 | $577.80 Million | +7.06% |
| 2018-12-31 | $539.68 Million | -- |
About Maravai Lifesciences Holdings Inc
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products fo… Read more